Skip to Main content Skip to Navigation
Journal articles

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

Abstract : PURPOSE: This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT). PATIENTS AND METHODS: Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT. RESULTS: With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively). CONCLUSION: We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00484234
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 18, 2010 - 10:56:33 AM
Last modification on : Thursday, November 12, 2020 - 9:42:08 AM

Identifiers

Citation

Patrice Chevallier, Mohamad Mohty, Bruno Lioure, Gérard Michel, Nathalie Contentin, et al.. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2008, 26 (30), pp.4940-3. ⟨10.1200/JCO.2007.15.6315⟩. ⟨inserm-00484234⟩

Share

Metrics

Record views

743